{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:55:24Z","timestamp":1761648924276,"version":"3.41.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Trazodone (TZD) is a tetracyclic serotonin antagonist and reuptake inhibitor that is used as a second-generation phenylpiperazine antidepressant. However, the plasma concentrations of TZD have shown individual variations in clinical practice. Quantification of TZD plasma concentrations may be an effective and valuable method to balance the clinical efficacy and adverse reactions. This study aimed to establish a novel liquid chromatography coupled with mass spectrometry (LC-MS) assay for measuring TZD concentrations in human plasma for therapeutic drug monitoring (TDM).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>After protein precipitation with acetonitrile, LC-MS quantification of TZD was performed in the multiple reaction monitoring mode with chromatographic separation using a mobile phase of MeOH and 0.1% formic acid in water. This method validation intends to investigate specificity, sensitivity, linearity, precision, accuracy, recovery, matrix effect, and stability according to United states food and drug administration guidelines.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>This method showed good selectivity because no interfering peaks were observed in the plasma samples during the 2-minute run time. The range of the calibration curve was 1\u20133000 ng\/mL. The detection and quantification limits were 0.3 and 1 ng\/mL, respectively. The intraday and interday accuracies were 96.5%\u2013103.4%, with precision relative SD% values of &lt;5%, except for the limit of quality. The mean TZD recovery from human plasma was 95.4%\u2013104.5%. Finally, this method was successfully applied to TDM in 20 patients. The TZD plasma concentrations of the patients ranged between 21.5 and 2267.3 ng\/mL.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>A novel analytical method was established to measure TZD by LC-MS coupled with an automatic 2-dimensional liquid chromatograph mass spectrometer coupler 9500 (LC-MS\/MS-Mate 9500), which is superior to the ordinary LC-MS system in separation, transport, anti-interference, sensitivity, and quantitative analysis stability.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000921","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T21:17:43Z","timestamp":1630531063000},"page":"465-473","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Development of a Novel Analytical Method for Determining Trazodone in Human Plasma by Liquid Chromatography Coupled With Mass Spectrometry Coupled With Automatic 2-Dimensional Liquid Chromatograph-Mass Spectrometer Coupler 9500 and Its Application to Therapeutic Drug Monitoring"],"prefix":"10.1097","volume":"44","author":[{"given":"Jing","family":"Ding","sequence":"first","affiliation":[{"name":"Xi'an Mental Health Center, Xi'an, P.R. China; and"},{"name":"Xi'an Key Laboratory of Pharmaceutical (Mental Health), Xi'an, P.R. China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Xi'an Mental Health Center, Xi'an, P.R. China; and"},{"name":"Xi'an Key Laboratory of Pharmaceutical (Mental Health), Xi'an, P.R. China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohua","family":"Cui","sequence":"additional","affiliation":[{"name":"Xi'an Mental Health Center, Xi'an, P.R. China; and"},{"name":"Xi'an Key Laboratory of Pharmaceutical (Mental Health), Xi'an, P.R. China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caiping","family":"Zhao","sequence":"additional","affiliation":[{"name":"Xi'an Mental Health Center, Xi'an, P.R. China; and"},{"name":"Xi'an Key Laboratory of Pharmaceutical (Mental Health), Xi'an, P.R. China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suo","family":"Zhang","sequence":"additional","affiliation":[{"name":"Xi'an Mental Health Center, Xi'an, P.R. China; and"},{"name":"Xi'an Key Laboratory of Pharmaceutical (Mental Health), Xi'an, P.R. China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2165\/00002512-199404040-00006","article-title":"Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders","volume":"4","author":"Haria","year":"1994","journal-title":"Drugs Aging"},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.neuropharm.2007.05.011","article-title":"Trazodone inhibits T-type calcium channels","volume":"53","author":"Kraus","year":"2007","journal-title":"Neuropharmacology"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s40263-012-0010-5","article-title":"Erratum to: rediscovering trazodone for the treatment of major depressive disorder","volume":"26","author":"Fagiolini","year":"2012","journal-title":"CNS Drugs"},{"key":"R4-20250603","first-page":"71","article-title":"Anxiety and depression: optimizing treatments","volume":"2","author":"Ballenger","year":"2000","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1517\/14656566.2012.699523","article-title":"Off-label uses of trazodone: a review","volume":"13","author":"Bossini","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jpba.2008.02.028","article-title":"HPLC analysis of the antidepressant trazodone and its main metabolite m-CPP in human plasma","volume":"47","author":"Mercolini","year":"2008","journal-title":"J Pharm Biomed Anal"},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1017\/S1092852900024020","article-title":"Mechanism of action of trazodone: a multifunctional drug","volume":"14","author":"Stahl","year":"2009","journal-title":"CNS Spectrums"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/BF02245475","article-title":"A comparison of trazodone and fluoxetine: implications for a serotonergic mechanis of antidepressant action","volume":"109","author":"Marek","year":"1992","journal-title":"Psychopharmacology"},{"key":"R9-20250603","first-page":"1","article-title":"Pharmacokinetics of single oral dose trazodone: a randomized, two-period, cross-over trial in healthy, adult, human volunteers under fed condition","volume":"6","author":"Prashant","year":"2015","journal-title":"Front Pharmacol"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.3390\/molecules25174026","article-title":"Review of chromatographic methods coupled with modern detection techniques applied in the therapeutic drugs monitoring (TDM)","volume":"25","author":"Tuzimski","year":"2020","journal-title":"Molecules"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0009-9120(96)00166-X","article-title":"Determination of trazodone and its metabolite, 1-m-Chlorophenyl-piperazine, in human plasma and red blood cell samples by HPLC","volume":"30","author":"Vatassery","year":"1997","journal-title":"Clin Biochem"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.chroma.2007.02.112","article-title":"Determination of trazodone in urine and pharmaceuticals using micellar liquid chromatography with fluorescence detection","volume":"1156","author":"Carda-Broch","year":"2007","journal-title":"J Chromatogr A"},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1080\/01483918708066744","article-title":"A simple HPLC method for the determination of trazodone human serum","volume":"10","author":"Lovett","year":"1987","journal-title":"J Liq Chromatog"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1365-2125.1981.tb01157.x","article-title":"Trazodone: a new assay procedure and some pharmacokinetic parameters","volume":"11","author":"Ankier","year":"1981","journal-title":"Br J Clin Pharmacol"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0378-4347(92)80161-I","article-title":"Measurement of trazodone in plasma and brain of rat by capillary gas chromatography with a nitrogen-selective detector","volume":"575","author":"Andriollo","year":"1992","journal-title":"J Chromatogr"},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1365-2125.1984.tb02485.x","article-title":"Comparative bioavailability of trazodone formulations using stable isotope methodology","volume":"18","author":"Gammans","year":"1984","journal-title":"Br J Clin Pharmacol"},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0378-4347(00)84657-5","article-title":"Gas chromatographic-mass spectrometric method for trazodone and a deuterated analogue in plasma","volume":"339","author":"Gammans","year":"1985","journal-title":"J Chromatogr"},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.chroma.2007.10.096","article-title":"Comparison of electron and chemical ionization modes by validation of a quantitative gas chromatographic-mass spectrometric assay of new generation antidepressants and their active metabolites in plasma","volume":"1176","author":"Wille","year":"2007","journal-title":"J Chromatogr A"},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0731-7085(01)00426-5","article-title":"Spectrophotometric, spectrofluorimetric and LC determination of trazodone hydrochloride","volume":"26","author":"El-Gindy","year":"2001","journal-title":"J Pharmaceut Biomed"},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.forsciint.2006.03.038","article-title":"Solid-phase extraction and analysis of 20 antidepressant drugs in human plasma by LC\/MS with SSI method","volume":"162","author":"Shinozuka","year":"2006","journal-title":"Forensic Sci Int"},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jchromb.2006.05.031","article-title":"Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: a multi-level, single-sample approach","volume":"843","author":"Kirchherr","year":"2006","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R23-20250603","first-page":"1","article-title":"Validated HPLC-MS\/MS method for determination of trazodone in human plasma","volume":"2","author":"Pvdls","year":"2013","journal-title":"Sci Rep"},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"16972","DOI":"10.1039\/C8NJ03545H","article-title":"Application of the UHPLC method for separation and characterization of major photolytic degradation products of trazodone by LC-MS and NMR","volume":"42","author":"Thummar","year":"2018","journal-title":"New J Chem"},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jchromb.2008.06.046","article-title":"High throughput and sensitive determination of trazodone and its primary metabolite, m-chlorophenylpiperazine, in human plasma by liquid chromatography-tandem mass spectrometry","volume":"871","author":"Patel","year":"2008","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R26-20250603","first-page":"300","article-title":"Determination of trazodone in human plasma by reversed-phase liquid chromatography-mass spectrometry with electrospray ionisation","volume":"6","author":"Kale","year":"2014","journal-title":"Int J Pharm Pharm Sci"},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/FTD.0b013e31823bf0fd","article-title":"Quantitative method validation for the analysis of 27 antidepressants and metabolites in plasma with ultraperformance liquid chromatography-tandem mass spectrometry","volume":"34","author":"del Mar Ram\u00edrez Fern\u00e1ndez","year":"2012","journal-title":"Ther Drug Monit"},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.4155\/bio.11.135","article-title":"Recommendations on: internal standard criteria, stability, incurred sample reanalysis and recent 483s by the Global CRO Council for Bioanalysis","volume":"3","author":"Lowes","year":"2011","journal-title":"Bioanalysis"},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jchromb.2006.12.030","article-title":"Systematic and comprehensive strategy for reducing matrix effects in LC\/MS\/MS analyses","volume":"852","author":"Chambers","year":"2007","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.talanta.2013.03.048","article-title":"Ion suppression; a critical review on causes, evaluation, prevention and applications","volume":"115","author":"Furey","year":"2013","journal-title":"Talanta"},{"key":"R32-20250603","first-page":"572","article-title":"Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources","volume":"26","author":"Rotzinger","year":"1998","journal-title":"Drug Metab Dispos"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000921","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:14:36Z","timestamp":1748970876000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000921","relation":{},"ISSN":["0163-4356"],"issn-type":[{"type":"print","value":"0163-4356"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"2021-03-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}